Comparison of disease‐modifying anti‐rheumatic drugs and hyperbaric oxygen therapy in the experimental model of rheumatoid arthritis in rats

Abstract

AbstractIn this study, we wanted to investigate the effectiveness of combining disease‐modifying anti‐rheumatic drugs (DMARD) with hyperbaric oxygen therapy (HBOT) in reducing inflammation in a rheumatoid arthritis (RA) model using rats. We divided 56 male Sprague–Dawley rats into seven groups and induced RA using complete Freund's adjuvant. Some groups received HBOT, whereas others were given etanercept or leflunomide. We started the treatment on the 10th day after inducing RA and continued it for 18 days. To evaluate the effectiveness of the treatments, we measured paw swelling and used X‐rays to examine the joints before and after the treatment. We also analysed the levels of two inflammatory markers, tumour necrosis factor (TNF)‐α and interleukin (IL)‐1β, using an enzyme‐linked immunosorbent assay. Additionally, we conducted histological analysis and assessed the expressions of anti‐IL‐1β and anti‐TNF‐α antibodies. All the treatment groups showed a significant decrease in arthritis scores, paw swelling and levels of TNF‐α and IL‐1β. The X‐ray images revealed improvements in joint structure, and the histopathological analysis showed reduced inflammation and collagen abnormalities. Combining DMARD with HBOT had similar effects to individual therapies, suggesting a cost‐effective and potentially safer approach for improving outcomes in rats with RA.